表面大蛋白在阿德福韦酯治疗慢性乙型肝炎中疗效观察的作用

目的 探讨阿德福韦酯(ADV)治疗慢性乙型肝炎过程中血清乙型肝炎表面大蛋白(LHBs)的变化与抗病毒疗效的关系.方法 分别检测30例用ADV抗病毒治疗的慢性乙型肝炎患者在0.6、12、18、24个月时的LHBs、HBV DblA、HBeAg水平.结果 30例患者在入组时的LHBs阳性检出率(90.00%)与HBVDNA的阳性检出率(100%)比较差异无统计学意义(x~2=3.16,P>0.05),LHBs的含量(吸光值)与HBV DNA拷贝数的对数呈正相关性(r=0.912).LHBs的阳性检出率与HBeAg的阳性检出率(80.00%)比较,差异无统计学意义(x~2=1.18,P>0.05).ADV抗病毒治疗0、6、12、18、24个月无效风险预测值分别为0.48、052、0.59、0.59、0.76.结论 血清LHBs与HBV DNA有较好的一致性,可作为一个新的判断病毒复制的指标.抗病毒治疗过程LHBs阳性持续时间越长,预示着抗病毒治疗无效的风险性越大.

Effects of serum hepatitis B virus large surface protein in therapeutic observation of adefovir dipivoxil on chronic hepatitis B

Objective To analyse the clinical value of HBV large surface protein(LHBs)in the therapeutic observation of adefovir dipivoxil on chronic hepatitis B.Methods The levels of serum LHBs、HBV DNA、 HBeAg of 30 chronic hepatitis B cases with anti-viral of adefovir dipivoxil were detected at the time of 0,6,12,18,24 months.Results There was no statistical difference between the positive rate of LHBs(90.00%) and HBV DNA(100%) (χ~2=3.16,P > 0.05).LHBs levels were correlated with the logarithm of HBV DNA copies (r=0.912).There was no statistical difference between the positive rate of HBeAg(80.00%)and LHBs(χ~2=1.18,P > 0.05).Conclusions The serum LHBs has a good consistency with HBV DNA.It can be used as a new indicator of viral replication.The long LHBs positive duration indicates the high risk of invalid anti-viral treatment.